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Abstract: 
Genistein, a flavonoid in legumes and some herbal medicines, has various biological actions. 
However, studies on whether genistein has an effect on pancreatic β-cell function are very 
limited. In the present study, we investigated the effect of genistein on β-cell proliferation and 
cellular signaling related to this effect and further determined its antidiabetic potential in insulin-
deficient diabetic mice. Genistein induced both INS1 and human islet β-cell proliferation after 24 
h of incubation, with 5 μm genistein inducing a maximal 27% increase. The effect of genistein 
on β-cell proliferation was neither dependent on estrogen receptors nor shared by 17β-estradiol 
or a host of structurally related flavonoid compounds. Pharmacological or molecular intervention 
of protein kinase A (PKA) or ERK1/2 completely abolished genistein-stimulated β-cell 
proliferation, suggesting that both molecules are essential for genistein action. Consistent with its 
effect on cell proliferation, genistein induced cAMP/PKA signaling and subsequent 
phosphorylation of ERK1/2 in both INS1 cells and human islets. Furthermore, genistein induced 
protein expression of cyclin D1, a major cell-cycle regulator essential for β-cell growth. Dietary 
intake of genistein significantly improved hyperglycemia, glucose tolerance, and blood insulin 
levels in streptozotocin-induced diabetic mice, concomitant with improved islet β-cell 
proliferation, survival, and mass. These results demonstrate that genistein may be a natural 
antidiabetic agent by directly modulating pancreatic β-cell function via activation of the 
cAMP/PKA-dependent ERK1/2 signaling pathway. 
Genistein may be a natural anti-diabetic agent by directly modulating pancreatic β-cell function 
via activation of the cAMP/PKA-dependent ERK1/2 signaling pathway. 
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Article: 
Genistein, an isoflavone in legumes and some Chinese herbal medicines, has well-known weak 
estrogenic effect and is a pharmacological inhibitor of tyrosine kinase. It has also been 
extensively explored for its potential hypolipidemic and antioxidative effects. Recent studies 
performed in animals (1) and humans (2) have shown that ingestion of isoflavones containing 
soy protein moderated hyperglycemia. However, it is not clear whether genistein primarily 
contributes to this beneficial effect. Emerging studies reported that administration of isoflavones 
or genistein lowered plasma glucose in diabetic animals (3, 4, 5) and postmenopausal women 
(6), suggesting that genistein may be a plant-derived antidiabetic agent. However, the 
mechanism of genistein action in diabetes is unknown. Whereas data from one study showed that 
genistein intake exerted a hypolipidemic effect in obese diabetic rats (3), other studies 
demonstrated that genistein lowered plasma glucose without affecting lipid profile or insulin 
sensitivity in obese diabetic animals (7) and humans (6). There is a line of evidence showing that 
oxidative stress and reactive oxygen species (ROS) play a potential role in the initiation of 
diabetes (8, 9, 10, 11). Genistein has been reported to exhibit antioxidant activity in aqueous 
phase systems (12, 13). However, the antioxidant effect of genistein is achieved only at 
concentrations ranging from 25 to 100 μm, suggesting that genistein is not a physiologically 
effective antioxidant because the achievable levels of total plasma genistein in both humans 
(14, 15) and rodents (16, 17) through dietary supplementation is no more than 10 μm. Indeed, 
intake of isoflavones has no antioxidative effect in healthy postmenopausal women (18). 
Consistently it has been shown that genistein is a relatively poor ROS scavenger (19, 20). 
Loss of β-cell mass and insulin secretory function, leading to the deterioration of glycemic 
control over time, is central to the development of both type 1 and type 2 diabetes (T2D) (21,22). 
Recent studies provided evidence that β-cells have the potential to regenerate by proliferation of 
preexisting β-cells in both physiological and pathological conditions (23, 24). As such, a strategy 
that induces β-cell proliferation, thus preserving functional β-cell mass, could be one of the 
essential strategies to prevent the onset of diabetes (21, 23, 25, 26, 27,28). Several earlier studies 
reported that genistein directly acts on β-cells, leading to insulin secretion (29, 30), whereas 
other studies found an inhibitory effect (31, 32). We recently discovered that genistein is a 
cAMP signaling agonist by activation of adenylate cyclase in pancreatic β-cells (33). It has been 
recently shown that several growth factors induce β-cell proliferation and exert their antidiabetic 
effects via activation of cAMP signaling (34, 35). Given this background, we investigated in the 
present study the effect of genistein on β-cell proliferation and cellular signaling related to this 
effect. 
Materials and Methods 
Cell and human islet culture 
INS1 cells were cultured as we previously described (33). Human pancreatic ductal cells 
(PANC1s), NIH3T3 preadipocytes (American Type Culture Collection, Manassas, VA), human 
aortic endothelial cells (HAECs), and rat vascular smooth muscle cells (RVSMCs; Lonza, 
Gaithersburg, MD) were grown using standard methods. Human islets were obtained through the 
National Institutes of Health-supported islet cell resource centers and the Islet Distribution 
Program at the Juvenile Diabetes Research Foundation. The islet purity was 80–90% and 
viability was 80–97%. Before the experiment, INS1 cells were synchronized in serum-free, 3 
mm glucose RPMI 1640 (Sigma, St. Louis, MO) for 24 h, and the islets were maintained in 
CMRL-1066 medium (Mediatech, Herndon, VA) containing 10% fetal bovine serum (HyClone, 
Logan, UT). 
Cell proliferation assay 
INS1 cells or human islets were incubated with various concentrations of genistein (Sigma) in 
RPMI 1640 at 37 C. The culture medium contained 1 mm glucose for INS1 cells and 2.8 
mmglucose for human islets. PANC1s, HAECs, and NIH3T3, and RVSMCs were incubated with 
genistein in RPMI 1640, M199, and DMEM, respectively. Twenty-four hours later, the cultures 
were continued for an additional 4 h in the presence of 5-bromo-2-deoxyuridine (BrdU; 10 μm). 
In some experiments, INS1 cells or the islets were preincubated with PD 098,059 (PD), H89, ICI 
182,780 (ICI), or vehicle (dimethyl sulfoxide) for 30 min before addition of 1 μm genistein for 
24 h. Cell proliferation was assessed by BrdU incorporation measurements with an ELISA kit 
(Roche Applied Science, Indianapolis, IN). 
In vitro free radical scavenging activity assay 
Free radical scavenging activity of genistein was determined by oxygen radical absorbance assay 
as described (36). 
Immunoblot analysis 
Equal amounts of protein from cell extracts were resolved on 10% SDS-PAGE gels, blotted onto 
nitrocellulose membranes, and probed with antiphospho-ERK1/2 or anticyclin D1 (Cell 
Signaling, Danvers, MA) as we previously described (37). Membranes were then stripped and 
reprobed with anti-ERK1/2 or anti-β-actin to monitor for equal sample loading. 
Intracellular cAMP and protein kinase A (PKA) activity assays 
Intracellular cAMP concentration and PKA activity in the lysates of human islets were measured 
as previously described (33). 
Antibody transfection 
Polyclonal antibodies against PKA catalyticα plus catalyticβ or preimmune IgG (Santa Cruz 
Biotechnology, Santa Cruz, CA) were transfected into INS1 cells using a Chariot reagent 
according to the manufacturer’s protocol (Active Motif, Carlsbad, CA). After 5 h in complete 
RPMI 1640 and 12 h in serum-free medium containing 3.0 mm glucose after transfection, the 
cells were treated with 1 μm genistein or vehicle for 24 h followed by cell proliferation assay. 
Adenoviral PKA inhibitor gene construct and infection 
Replication-deficient adenovirus containing the complete sequence of endogenous PKA inhibitor 
cDNA (AdPKI) was constructed as previously described (38). For determining infection 
efficiency, human islets were exposed to purified adenovirus at 100–400 multiplicity of infection 
(MOI)/cells in RPMI 1640 medium for 1 h at 37 C and then cultured in RPMI 1640 containing 
5% fetal bovine serum for 24 h at 37 C. AdPKI null virus served as controls. For MOI 
calculation, it was assumed that each islet equivalent consists of 1000 cells. After infection, the 
islets were treated with 10 μm forskolin and 0.2 mm 3-isobutyl-1-methylxanthine for 15 min. 
The enzymatic activity of PKA in the lysates of islets was determined. For proliferation assay, 
islets were infected with AdPKI or AdPKI null virus at 200 MOI/cell and then treated with 1 
μm genistein or vehicle for 24 h. 
Animals and treatment with genistein 
Four-week-old male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were housed in a 
room maintained on a 12-h light, 12-h dark cycle under constant temperature (22–25 C) withad 
libitum access to food and water. The protocol of this study was approved by the Institutional 
Animal Care and Use Committee at Virginia Polytechnic Institute and State University. Mice 
were initially fed a modified AIN-93G rodent diet with corn oil substituted for soybean oil (Dyet, 
Inc., Bethlehem, PA) for 2 wk and then were randomly divided into three groups with 12 mice 
per group and fed a diet containing either 0 g (groups 1 and 2) or 0.25 g (group 3) genistein per 
kilogram. This genistein dosage was used (approximately a human intake of 25–200 mg/d) 
because it is within the range that humans can realistically consume through taking supplements 
(39). We confirmed by performing HPLC analysis that the basal diet is free of genistein. After 2 
wk, diabetic mice were induced with ip injection of streptozotocin (STZ) dissolved in 0.1 
mm cold sodium citrate buffer (pH 4.5) at 40 mg/kg daily for 5 consecutive days. Control mice 
received ip citrate buffer. After this procedure, mice were continually treated with the control or 
genistein diet. Body weight and feed intake were recorded weekly throughout the study. To 
confirm the results, we repeated this animal experiment using the same study protocols. 
Plasma glucose, insulin, and lipid measurements 
At the beginning of the experiment, the fasting blood glucose levels in tail vein blood sample 
were measured using a glucometer (Roche) to ensure that the mice were euglycemic. After STZ 
injection, the levels of blood glucose were measured weekly to assess the onset of hyperglycemia 
(nonfasting blood glucose > 250 mg/dl) (40). Plasma insulin concentration was measured by 
ELISA (Mecodia, Winston-Salem, NC) in mice fasted for 4 h. Fasting plasma total cholesterol 
and triacylglycerides were measured in triplicate by enzymatic methods using a Pointer 180 
analyzer (Pointe Scientific, Canton, MI) as described (41). 
Plasma genistein measurements 
Blood samples were drawn 2 h after food intake from the retrobulbar plexus through heparinized 
capillary tubes. Plasma was collected by centrifugation at 16,000 × g for 15 min. An aliquot of 
250 μl serum per sample was used for extraction of genistein using a previously described 
method (42). Genistein in the extracted samples was determined by using the HPLC system 
(Waters2695; Waters Co., Milford, MA) with a Luna phenyl-hexyl column (5 μm C18 100 Å; 
Phenomenex Inc., Torrance, CA) (43). 
Glucose and insulin tolerance tests 
For glucose tolerance tests, mice were fasted 4 h and injected ip with a single bolus of glucose (2 
g/kg body weight). Glucose levels were measured at time points of 0, 15, 30, 60, and 120 min 
after glucose administration. For insulin tolerances tests, mice were injected ip with insulin (0.75 
U/kg body weight), and blood glucose levels were measured at 0, 15, 30, 60, and 120 min after 
insulin administration. 
Hepatic antioxidant and other enzyme assays 
The harvested livers were homogenized in ice-cold 50 mm phosphate buffer containing 2 
mmEDTA on ice and then centrifuged at 10,000 × g for 15 min at 4 C. The resulting 
supernatants were collected and kept on ice for measuring the level of glutathione (GSH) and 
activity of GSH reductase (GR), GSH peroxidase (GPx), GSH S-transferase (GST), catalase, 
superoxide dismutase, and nicotinamide adenine dinucleotide phosphate oxidase-quinone 
oxidoreductase 1 (NQO1) as previously described (44). 
Immunohistochemistry and islet morphometry 
Twelve mice per group were injected (ip) with BrdU (100 mg/kg body weight). Ten hours after 
injection, the pancreata were dissected, fixed in 4% (vol/vol) formaldehyde buffer (pH 7.2), and 
embedded in paraffin. A series of tissue sections (5 μm thickness) were prepared; mounted on 
glass slides; and immunofluorescently stained for determining β-cell mass, proliferation, and 
apoptosis. The β-cell area was measured using images acquired from serial insulin-stained 
pancreatic sections (500 μm interval). The β-cell mass was calculated by dividing the area of 
insulin-positive cells by the total area of pancreatic tissue and multiplying by the pancreas weight 
(45). Proliferating β-cells were identified by examining the incorporation of BrdU in β-cells, 
which was determined by sequential immunolabeling pancreatic sections with sheep anti-BrdU 
and guinea pig antiinsulin antibodies (Abcam, Cambridge, MA) (46). Apoptotic β-cells were 
detected by labeling the sections with a terminal deoxynucleotidyl transferase-mediated 
deoxyuridine 5-triphosphate nick-end labeling (TUNEL) kit (Roche Applied Science) as 
described (47), followed by staining with a guinea pig antiinsulin antibody to visualize β-cells. 
Statistical analysis 
Data were analyzed with one-way ANOVA or Student’s paired t test when designated using SAS 
program (SAS Institute, Cary, NC). Treatment differences were subjected to Tukey’s test. A P < 
0.05 was considered significant. 
Results 
Genistein stimulates β-cell proliferation 
We first examined whether genistein has an effect on clonal β-cell proliferation. As shown in 
Fig. 1A, genistein dose-dependently stimulated INS1 cell proliferation. The effect of genistein on 
β-cell proliferation was significant at 0.1 μm concentration, with a maximal increase at 5 
μmgenistein (27% over control, P < 0.01). We further evaluated the nuclear event that mediates 
genistein effect on cell proliferation and found that exposure of INS1 cells to genistein for 3 h 
elicited a 61.6% increase (P < 0.05) in the expression of cyclin D1 protein (Fig. 1B), a major 
cell-cycle regulator essential for β-cell growth (48), suggesting that genistein may stimulate cell 
cycle progress involving cyclin D1expression. We considered the possibility that the stimulation 
of genistein on β-cell proliferation might simply represent the repair of oxidation-induced 
damage to the DNA. Our studies excluded this possibility based on these observations. First, we 
directly counted the cells using a microscope cell counting chamber after genistein treatment. We 
observed that exposure of INS1 cells to genistein (1 and 5 μm) increased cell number by 28.9–
35.6%. Second, we observed that exposure of genistein to β-cells for 24 h had no effect on cell 
viability (data not shown), suggesting that the increased cell proliferation by genistein is not due 
to a change in cell apoptosis. Third, whereas pharmacological dose of genistein (10–20 μm) 
showed significant free radical scavenging activity, it had no effect at 1 μm (data not shown). 
Fourth, as described below, a variety of flavonoids that are reportedly potent antioxidants failed 
to stimulate β-cell proliferation (Fig. 2). 
 
Fig. 1. Genistein (Gen) stimulates proliferation of β-cells. A, INS1 cells were incubated with 
various concentrations of Gen or vehicle in RPMI 1640 medium for 24 h, followed by addition 
of BrdU (10 μm) for 4 h. Cell proliferation were determined by measuring DNA synthesis using 
BrdU ELISA kit. Data were expressed as mean ± se of observations from four to five separate 
experiments, each performed in triplicate sample. B, INS1 cells were incubated with Gen (1 μm) 
or vehicle [control (C)] for 3 h. The level of cyclin D1 in the treated cell extracts was measured 
by Western blot and normalized to β-actin content from the same sample. The bar graphs (mean 
± se) represent four independent experiments. *, P < 0.05 vs. vehicle-alone-treated control. 
 
Fig. 2. The stimulatory effect of genistein on β-cell growth may be structure specific. INS1 cells 
were cultured with various flavonoids (1 μm) in RPMI 1640 containing 1 mm glucose for 24 h. 
Cell proliferation was determined using an ELISA kit. Data are expressed as mean ± se derived 
from three independent experiments performed in triplicate each. *, P < 0.05 vs. vehicle-alone-
treated cells. 
Genistein has no effect on the proliferation of PANC1s, NIH3T3, HAECs, and RVSMCs 
Increased cell proliferation may not always be desirable for other tissues. We therefore tested the 
effects of genistein on proliferation of PANC1s, NIH3T3, HAECs, and RVSMCs. We found that 
genistein at the same doses used for β-cell proliferation study had no effect on proliferation of 
these cells (data not shown), suggesting that the stimulatory effect of genistein on cell 
proliferation may be restricted to β-cells. 
The stimulatory effect of genistein on β-cell proliferation may be structure specific 
To determine the specificity of this genistein effect, we tested a host of structurally related 
flavonoid compounds in parallel to genistein. This analysis revealed the following data (Fig. 2): 
1) isoflavones [genistin (a glycoside form of genistein) and biochanin A (a precursor of 
genistein), which are largely converted to genistein in the intestine (49), increased INS1 cell 
proliferation by 25 and 27%, respectively, a magnitude comparable with that of genistein (24%), 
whereas formononetin, glycerin, and equol had no effect; 2) flavones (quercetin and kaempferol) 
slightly decreased cell proliferation by 15.8 and 12.7%, respectively; 3) flavanols (epicatechin, 
epicatechin gallate, epigallacatechin, epigallacatechin gallate) had no effect; 4) resveratrol, a 
natural phytoalexin, was also inactive. These results demonstrated the unique effect of genistein 
on β-cell growth that is possibly not shared by other structurally related flavonoid compounds. 
Estrogen receptor (ER)-independent effect of genistein on β-cell proliferation 
Because genistein has well-known weak estrogenic effects in some tissues by binding to ERs 
(50), we examined whether genistein-induced cell proliferation was mediated through ERs. As 
shown in Fig. 3A, genistein increased INS1 cell proliferation by about 30%. The ER antagonist 
ICI had no effect on genistein-induced cell proliferation. The activity of ICI used in this study 
was validated through blocking 17β-estradiol-induced Akt phosphorylation in endothelial cells as 
we recently demonstrated (51). In addition, exposure of INS1 cells to 17β-estradiol for 24 h 
failed to stimulate cell proliferation (Fig. 3B). These results suggest that the effect of genistein 
on β-cell proliferation is independent of estrogen signaling mechanisms. 
 
Fig. 3. Genistein (G)-induced β-cell proliferation is ER independent. A, INS1 cells were 
preincubated with ICI (I; 2 μm) or vehicle for 30 min, followed by addition of G (1 μm) or 
vehicle (C). B, INS1 cells were incubated with G (1 μm), 17β-estradiol (E1; 1 nm; E10; 10 nm) 
or vehicle (C) in RPMI 1640 containing 1 mm glucose. Twenty-four hours later, cell 
proliferation was measured with ELISA. Data obtained from five separate experiments in 
triplicate determinations each are expressed as mean ± se. *, P < 0.05 vs. vehicle-alone-treated 
cells. 
Stimulation of β-cell proliferation by genistein is mediated through PKA-dependent 
activation of ERK1/2 signaling 
Recent studies suggested that the cAMP/PKA- and ERK1/2-mediated pathways are two 
important signaling cascades mediating various stimuli-induced β-cell proliferation (52). We 
recently reported that genistein activates the cAMP/PKA signaling in clonal β-cells and mouse 
islets (33). Here we showed that incubation of INS1 cells in genistein for 15 min stimulated the 
phosphorylation of ERK1/2, with 5 μm genistein inducing a maximal increase (Fig. 4A), a 
pattern that is consistent with its effect on cell proliferation. However, the expression of ERK1/2 
protein was not changed in these studies (Fig. 4B). 
Next, we determined whether the activation of cAMP and ERK1/2 signaling is involved in 
genistein-induced β-cell proliferation. We showed that incubation of INS1 cells with the PKA 
inhibitor H89 or the MAPK kinase (MEK)-1/2 inhibitor PD completely abolished the genistein-
stimulated proliferation of INS1 cells (Fig. 4C). Consistent with this result, inhibition of PKA or 
MEK1/2 blocked genistein-induced phosphorylation of ERK1/2 (Fig. 4D), suggesting that PKA 
acts upstream of MEK1/2 to mediate ERK1/2 phosphorylation and subsequent cell proliferation. 
To further confirm the role of PKA, we delivered PKA Cα- plus Cβ-antibodies into INS1 cells 
(33). Transfection of the cells with PKA antibodies significantly attenuated genistein-induced β-
cell proliferation (Fig. 4E), whereas preimmune IgG had no effect. These results indicate that 
activation of PKA is sufficient for genistein-induced β-cell proliferation. 
 
Fig. 4. Genistein (Gen)-stimulated β-cell proliferation is mediated through the PKA and ERK1/2 
signaling mechanisms. A, INS1 cells were incubated in RPMI 1640 containing 1 mm glucose 
with various concentrations of Gen for 15 min at 37 C. Western analysis was performed per 
protocol described in Materials and Methods to detect phosphorylated ERK1/2 (P-ERK1/2), 
which was normalized to total ERK 1/2 (B) from the same sample. C and D, INS1 cells were 
preincubated with PD (2 μm), H89 (H; 10 μm) or vehicle (Control) for 30 min. Cells were then 
treated with Gen (1 μm) or vehicle (Control) in the continued presence or absence of inhibitors at 
37 C. Incubation was either terminated after 15 min to determine ERK1/2 phosphorylation by 
Western blotting or continued for 24 h to determine cell proliferation. E, INS1 cells were 
transfected with antibodies against PKA Cα plus Cβ or preimmune IgG per protocol as described 
in Materials and Methods. Transfected cells were treated with Gen (1 μm) or vehicle for 24 h 
followed by performing cell proliferation assay. Data are expressed as mean ± se of three to six 
experiments in triplicate each. *, P< 0.05 vs. vehicle alone or preimmune IgG-alone-treated cells. 
Genistein activates cAMP and ERK1/2 signaling and subsequently stimulates human islet 
cell proliferation 
We tested whether genistein has a similar effect on cell proliferation in human pancreatic islets. 
As shown in Fig. 5A, genistein significantly induced cell proliferation in human islets, with 5 
μm genistein inducing 44.5% increase in cell proliferation over control. Because not all cells in 
the islets are β-cells, we performed an immunofluorescence study to determine whether cell 
proliferation in islets induced by genistein is β-cell specific. Islets treated with or without 
genistein were double immunostained with BrdU and insulin antibodies. The result showed that 
proliferative cells in human islets induced by genistein are β-cells (Fig. 5B). 
To determine whether the same signaling pathways that mediate genistein effect on INS1 cell 
proliferation also operate in human islets, we first tested whether genistein elevates intracellular 
cAMP levels and activates PKA in human islets. The result showed that genistein also 
significantly elevated cAMP (Fig. 5C) and induced PKA activity (Fig. 5, D and E), consistent 
with the dose-response pattern as that obtained in islet proliferation study. 
To determine the role of PKA and ERK1/2 in the regulation of genistein effect in human islets, 
we incubated the islets with genistein in the presence or absence of PD or H89 for 24 h. In line 
with observations in INS1 cells, inhibition of MEK1/2 or PKA completely abolished the 
genistein-stimulated cell proliferation (Fig. 5F) and ERK1/2 phosphorylation in human islets 
(Fig. 5G), further confirming a central role of PKA and a cross talk between cAMP/PKA and 
MEK/ERK signaling pathways in mediating genistein action. To further confirm the role of PKA 
in mediating this genistein effect, human islets were infected with AdPKI. Treatment of islets 
with AdPKI greatly attenuated PKA activity (Fig. 5H) and genistein-induced cell proliferation 
(Fig. 5I), whereas control virus was inactive. Taken together, these results indicate that genistein 
induces islet β-cell proliferation via activation of the cAMP/PKA/MEK/ERK signaling cascade. 
 
Fig. 5. Genistein (Gen) stimulates intracellular cAMP accumulation, activates PKA and ERK1/2, 
and subsequently stimulates cell proliferation in human islets. Human islets were incubated with 
various concentrations of Gen; panel A or 1 μm Gen panel B in RPMI 1640 containing 2.8 
mmglucose for 24 h, followed by labeling with BrdU (10 μm) for 4 h. Islet cell proliferation was 
either measured by ELISA (panel A) or visualized by double immunostaining for BrdU (green) 
and insulin (red) (panel B). The light green BrdU+ nuclei as identified by the arrows from 
merged images (brown) show that Gen increases β-cell proliferation. C, Vehicle (control). Panels 
C and D, Human islets were stimulated with various concentrations of Gen or vehicle in RPMI 
1640 in the presence of 2.8 mm glucose at 37 C for 20 min. Intracellular cAMP concentration 
(panel C) and PKA activity (panel D) in cell extracts were measured, with a representative 
photograph of the agar gel used for PKA activity assay shown (panel E). Panels F and G, Human 
islets were preincubated with PD (10 μm), H89 (H; 10 μm), or vehicle (control) for 30 min. The 
islets were then stimulated with Gen 1 μm) or vehicle (control) in the continued presence or 
absence of inhibitors. Incubation was either terminated after 20 min to determine ERK1/2 
phosphorylation by Western blotting (panel G) or continued for 24 h to determine cell 
proliferation by ELISA (panel F). Panel H, Human islets were infected with 0, 100, 200, 400 
MOI AdPKI/cell, or control virus (N-AdPKI), followed by incubation with 10 μm forskolin and 
0.2 mm 3-isobutyl-1-methylxanthine for 15 min. PKA activity in the cell lysates was then 
determined by measuring phosphorylation of kemptide (P-kemp). Panel I, Human islets were 
infected with 200 MOI AdPKI/cell and then treated with Gen (1 μm) or vehicle for 24 h, 
followed by cell proliferation assay. Data are expressed as mean ± se obtained from three to four 
independent experiments in triplicate each. *, P < 0.05 vs. vehicle-alone-treated cells; #, P< 
0.05 vs. genistein-alone-treated cells. 
Dietary genistein intake ameliorates hyperglycemia in STZ-induced diabetic mice 
To investigate whether our in vitro and ex vivo findings are biologically relevant, we performed 
an animal study assessing whether genistein has potential to prevent diabetes. As expected, 
dietary supplementation of genistein significantly elevated plasma genistein levels. Under our 
experimental conditions, plasma genistein levels in STZ-induced diabetic mice fed basal or 0.25 
g/kg genistein diet were 0 and 6.84 ± 0.59 μm, respectively. Our data showed that genistein 
significantly ameliorated STZ-induced hyperglycemia in diabetic mice (Fig. 6A). By the 28th 
day after STZ injection, 88% of STZ-alone-treated mice became hyperglycemic, whereas only 
13% were diabetic in the genistein-treated group. Consistently, dietary genistein ingestion 
prevented body weight loss (Fig. 6B), whereas food intake was not affected in diabetic mice 
(data not shown). Mice fed genistein showed significantly higher blood insulin levels (Fig. 6C) 
and improved glucose tolerance (Fig. 6D), whereas insulin tolerance was not altered by genistein 
treatment (data not shown), suggesting that genistein has no effect on insulin sensitivity. To 
confirm the results from this study, we conducted a second animal trial and similar results were 
obtained. 
 
Fig. 6. Dietary intake of genistein (Gen) prevents STZ-induced diabetes in mice. Male C57B/6J 
mice (4 wk old) were fed a control diet (C; STZ) or Gen-supplemented diet (0.25 g/kg diet) for 2 
wk before administration of STZ (40 mg/kg body weight for 5 d) and continued on the same diet 
for 4 wk. The mice in the control group were injected with citrate buffer. Panel A, Nonfasting 
blood glucose levels were measured before and 1, 2, 3, and 4 wk after STZ administration. Panel 
B, Body weight gain was measured weekly during the whole period of animal study. Panel C, 
Plasma insulin levels in fasted mice were measured by ELISA. Panel D, Glucose tolerance was 
determined. Data are expressed as mean ± se (n = 12 mice). *, P< 0.05 vs. healthy control; #, P < 
0.05 vs. STZ-alone-treated mice. 
The antidiabetic effect of genistein is not due to modulating plasma lipid profiles or 
scavenging ROS 
We first measured plasma lipid levels in mice treated or untreated with genistein. The results 
showed that genistein had no effect on plasma cholesterol (Fig. 7A) and triglyceride 
concentrations (Fig. 7B). We have not observed significant differences in body weight and food 
intake between control and healthy mice fed a diet containing 0.25 g/kg genistein (data not 
shown). This result suggests that a moderate level of dietary genistein used in this study had no 
effect on appetite, energy expenditure, or lipogenesis, although it can reduce adipose deposition 
at higher doses (0.5–1.5 g/kg diet) in mice (17). Next, we evaluated hepatic antioxidant defense 
system in these animals. Our data demonstrated that genistein intake had no significant effects on 
the activities of NQO1, GST, GPx, GR, and catalase that play important role in scavenging ROS 
(Fig. 7C), although the activities of some of these enzymes were significantly increased in 
diabetic mice compared with normal mice. 
 
Fig. 7. Genistein (Gen) has no effect on plasma lipid profiles and hepatic antioxidant enzyme 
activities in STZ-induced diabetic mice. Diabetic mice were induced with STZ and fed a basal or 
Gen diet as described in Fig. 6. Plasma total cholesterol (panel A), triglycerides (panel B), and 
hepatic activities of GST, NQO1, GSH, GR, GPx, and catalase (panel C) were measured as 
described in Materials and Methods. Data are expressed as mean ± se (n = 6–8 mice). *, P < 
0.05 vs. healthy control (C). 
Dietary intake of genistein improves pancreatic β-cell proliferation, survival, and mass in 
diabetic mice 
We evaluated pancreatic islet cell mass through the immunohistochemical technique. We found 
that STZ administration severely decreased β-cell mass and disrupted the islet architecture (Fig. 
8, A and B), which is essential for normal islet function. However, dietary provision of genistein 
significantly improved islet β-cell mass. Next, we measured the proliferation and apoptosis of β-
cells, which may represent the mechanisms by which genistein improves β-cell mass. STZ 
treatment increased residual β-cell proliferation, an observation consistent with previous findings 
that destruction of β-cells by STZ leads to subsequent regeneration of β-cell mass primarily from 
proliferation of preexisting and surviving β-cells (53, 54, 55). Dietary provision of genistein 
significantly enhanced islet β-cell proliferation (Fig. 8, C and D). Furthermore, we performed in 
situ detection of DNA fragmentation by TUNEL assay to assess whether genistein has an effect 
on apoptosis of mouse islets. In addition, the islets were costained for insulin to identify β-cells. 
Genistein significantly reduced STZ-induced β-cell apoptosis (Fig. 8, E and F). This result 
suggests that genistein may improve pancreatic β-cell mass in diabetic mice through its 
mitogenic and antiapoptotic effects on islet β-cells. 
 
Fig. 8. Dietary intake of genistein (Gen) improves pancreatic β-cell proliferation, survival, and 
mass in STZ-induced diabetic mice. Panels A and B, Pancreatic sections from control (C) or STZ 
diabetic mice fed control or Gen diet were stained with an antibody against insulin. The β-cell 
mass was determined as described in Materials and Methods. Panels C and D, Pancreatic 
sections were double immunostained for BrdU and insulin. The number of BrdU- and insulin-
positive cells as identified by the arrows from merged images was counted. Panels E and F, 
Pancreatic sections were stained using TUNEL procedure and costained for insulin. TUNEL- 
and insulin-positive cells were identified by the arrows in merged sections (panel E). The 
number of apoptotic β-cells in each islet was counted and expressed as percentage of total 
insulin-positive cells (panel F). Data are expressed as mean ± se (n = 12 mice). *, P < 
0.05 vs. healthy control (C); #, P < 0.05 vs. STZ alone-treated mice 
Discussion 
Recent studies have shown that genistein may have antidiabetic potential (3, 4, 5, 6, 7). 
However, the mechanism of this effect is not understood. Here we provide evidence that 
genistein stimulates both clonal and human islet β-cell proliferation through the cAMP/PKA- 
and ERK1/2-dependent mechanisms. Recent studies demonstrated that loss of β-cell mass and 
function is central to the development of both type 1 diabetes and T2D (21, 22). Therefore, 
induction of β-cell proliferation is one of the essential strategies to prevent diabetes (21, 56). Our 
data from animal studies showing that genistein can act as a growth factor for β-cells in 
vivo provide a novel mechanism for the observed antidiabetic effect of this compound. 
Genistein is a widely used dietary supplement. The reported plasma concentrations of genistein 
in both humans (15) and rodents (17) through dietary supplementation are usually within the 
range of 1–5 μm. To consider the potential biological relevance of the observed effects of 
genistein on β-cell proliferation, we used genistein concentrations that are comparable with the 
physiologically achievable levels through dietary means. Whereas there is a trend for genistein to 
stimulate β-cell proliferation at 0.1 μm, a significant effect was observed at 1 μm, with the 
maximal effect achieved at 5 μm genistein. The results observed in INS1 cells were confirmed 
with isolated human islets, suggesting that physiologically relevant concentrations of genistein 
may have antidiabetic implications by directly acting as a β-cell growth factor. In addition, these 
data may provide a molecular basis for some of the antidiabetic effects of genistein observed 
recently in human and animal studies (3, 4, 5). 
The result from comparing the effect of genistein on β-cell proliferation with a cohort of 
structurally related flavonoids demonstrated a highly specific genistein effect. Although the 
specific chemical structure responsible for the β-cell proliferative effect of genistein remains to 
be determined, the hydroxyl group at the 5C position on the A ring may be crucial for the unique 
effect of genistein because equol and 17β-estradiol, which lack a hydroxyl group at 5C, failed to 
induce β-cell proliferation. In addition, we showed that replacing the hydroxyl group at either 7C 
position with a glucose molecule (genistin) or at 4C position with a methyl group (biochanin A) 
had no significant effect on genistein activity, suggesting that these structure components may 
not be important for genistein action. 
Genistein has well-known weak estrogenic effects by binding to ERs. However, we provided 
evidence that the observed proliferative effect of genistein on β-cells is not related to its potential 
estrogenic effect. Interestingly, recent studies reported that genistein can activate an orphan G 
protein-coupled receptor 30 (GPR30) (58). Whereas the physiological role of GPR30 is still 
unknown, female GPR30 knockout mice display hyperglycemia and impaired glucose tolerance 
(59). Therefore, it is intriguing to speculate that GPR30 may play a role mediating genistein 
effect. 
Activated ERK1/2 plays a pivotal role in environmentally stimulated cellular responses, 
including cellular proliferation, growth, and differentiation. We observed that genistein induced a 
rapid ERK1/2 phosphorylation, which was sustained for at least 6 h. Such a prolonged ERK1/2 
activation may be necessary for growth factors to drive β-cell proliferation (60). ERK1/2 can be 
activated by various different mechanisms (34). In this report, we found that genistein-stimulated 
ERK1/2 phosphorylation was dependent on PKA activation in β-cells, suggesting that ERK1/2 is 
located downstream of PKA, which is generally cAMP dependent. Cell growth and division are 
regulated by an array of D-type cyclins, cyclin-dependent protein kinases, and inhibitors of 
cyclin-dependent protein kinases. In the islets, cyclin D1 and D2 are essential for β-cell growth 
(48), and cyclin D1 alone can induce β-cell proliferation in rat and human islets (61). Whereas 
the mechanisms that link genistein to the cell cycle machinery are still unclear, we found that 
genistein elevated cyclin D1 protein expression. Previous studies demonstrated that cyclin D1 is 
a nuclear target of activated ERK1/2 (62). In addition, cAMP-responsive element sites (CREs) 
are present within cyclin D1 promoters, which are trans-activated by CRE-binding protein to 
regulate cyclin D1 gene expression (63). In β-cells, both PKA and ERK1/2 can induce CRE-
binding protein phosphorylation at serine 133, which is required for CRE-regulated transcription 
(64). Therefore, it is tempting to speculate that genistein may stimulate cell cycle progress at 
least partially through regulating cyclin D1 expression via activation of the PKA and ERK1/2 
cascades, although we cannot exclude the possibility that genistein also modulates other nuclear 
molecules involved in β-cell proliferation. 
Using a diabetic mouse model induced by multiple low doses of STZ, which causes mild to 
moderate level of diabetes mediated by a destruction of islet β-cells (40), we provided evidence 
that dietary supplementation of genistein could ameliorate diabetes and improve glucose 
tolerance, which are likely a result of improved functional β-cell mass by genistein treatment. 
Consistently, diabetic mice fed genistein displayed about 2-fold increase in circulating insulin 
levels compared with those in the control group, which, however, could be partially due to 
improved insulin secretion from existing β-cells by genistein, as observed in our previous studies 
(33). We further found that diabetic mice fed genistein exhibited greater islet β-cell proliferation 
and reduced levels of β-cell apoptosis caused by STZ, which should primarily contribute to 
improved β-cell mass observed in genistein-treated mice. However, the relative contributions of 
proliferative and antiapoptotic effects of genistein to the improved β-cell mass in diabetic mice 
cannot be established in this study. Whereas we provide sufficient evidence that genistein 
directly induces pancreatic β-cell proliferation ex vivo, suggesting that genistein improvement of 
pancreatic β-cell mass in vivo might be partially attributable to its growth-promoting effect on β-
cells, there is a possibility that observed mitogenic effect of genistein on β-cells in diabetic mice 
may simply represent enhanced repair of STZ-induced damage to the DNA or a protective effect 
on replicating β-cells. Further studies are needed to determine whether genistein improvement of 
pancreatic β-cell mass is primarily due to the promotion of compensatory growth of β-cells or 
protection of proliferating β-cells after islet injury. 
Because blood lipids could be risk factors for the pathogenesis of diabetes, the secondary action 
whereby genistein improves lipid profiles of diabetic animals may contribute to the overall 
antidiabetic effects of this agent. We considered this possibility and measured plasma lipid 
levels. However, we did not find that genistein lowered plasma lipid levels or improved insulin 
sensitivity. Oxidative stress may play a potential role in the initiation of diabetes (8). STZ may 
induce oxidative stress in diabetic mice, which may contribute to the diabetogenic effect of this 
agent. Whereas genistein at physiologically relevant concentrations (<5 μm) is a poor ROS 
scavenger (65), its biological effects are frequently attributed to a presumably antioxidant 
activity. We considered the possibility that the antidiabetic effect of genistein might partially be 
due to a reduced tissue damage caused by STZ-induced oxidative stress and therefore evaluated 
hepatic antioxidant defense system in mice treated or untreated with genistein. Although the 
activities of some of these enzymes were significantly increased in diabetic mice compared with 
normal mice, which may reflect an adaptive mechanism in response to elevated oxidative stress, 
genistein intake had no further effects on these enzymes, further confirming that the antidiabetic 
effect of was likely a result of improved functional β-cells in diabetic mice. 
The glucose analog STZ is reported to be transported into β-cells by the glucose transporter 2 
(GLUT2) for exerting its apoptotic effect (66). Although we did not study the effect of genistein 
on GLUT2 protein expression in mouse islets, our recent studies found no such effect in cultured 
β-cells (67), suggesting that improvement of islet β-cell mass and survival by genistein may not 
be due to modulation of GLUT2 expression, thereby preventing STZ influx in β-cells. Some 
studies showed that STZ increased peripheral lymphocytic infiltration into islets, thereby 
producing insulitis (40, 68), which may contribute to STZ-induced β-cell apoptosis and diabetes. 
However, we observed no effect of genistein on mononuclear cell infiltration into the islets. In 
fact, we detected hardly any infiltrated immune cells in these mice (data not shown), consistent 
with previous finding that this mouse strain is resistant to STZ-induced insulitis (57). 
In summary, we have identified for the first time that genistein may be a putative β-cell growth 
factor by targeting the cAMP and ERK1/2 signaling pathways. Our animal studies showed that 
genistein is capable of preserving islet β-cell mass and alleviating diabetes. Loss of functional β-
cell mass through apoptosis is central to the development of both type 1 diabetes and T2D and 
islet β-cell proliferation is a very important component of β-cell adaptation to increased 
apoptosis and insulin resistance and therefore holds promise as a treatment for this disease. In 
this context, these findings may potentially lead to the development of novel, natural agents for 
diabetes prevention and treatment. 
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